Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin

Abstract

Myeloid malignancies in children include de novo acute/chronic myeloid leukemia (AML/CML) and secondary malignancy due to genetic predisposition or previous therapy. Generations of clinical trials for childhood myeloid disorders have resulted in improved disease characterization and outcome, and defined therapeutic strategies combining chemotherapy, biologic response modifiers and immunotherapy. With advancement in molecular genetics and the development of sensitive techniques to detect response, residual disease and relapse, therapy can be tailored in a risk-based manner using clinical and biological/molecular parameters and several ‘good-risk’ myeloid malignancies enjoy high cure rates with targeted therapy. However, hematopoietic stem cell transplant remains the best method of treatment intensification for poor-risk disorders such as relapsed/secondary AML, myelodysplastic syndrome and juvenile myelomonocytic leukemia. Indications for transplant and outcomes of previous clinical studies, and novel transplant strategies designed to improve safety and efficacy of the procedure are reviewed.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Meshinchi S, Arceci R . Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 2007; 12: 341–355.

    Article  Google Scholar 

  2. Neudorf S, Sanders J, Kobrinsky N, Alonzo T, Buxton A, Buckley J et al. Autologous bone marrow transplantation for children with AML in first remission. Bone Marrow Transplant 2007; 40: 313–318.

    Article  CAS  Google Scholar 

  3. Godder K, Eapen M, Laver J, Zhang M, Camitta B, Wayne A et al. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. J Clin Oncol 2004; 22: 3798–3804.

    Article  Google Scholar 

  4. Gibson B, Wheatley K, Hann I, Stevens R, Webb D, Hills R et al. Treatment strategy and long-term results in pediatric patients treated in consecutive AML trials. Leukemia 2005; 19: 2130–2138.

    Article  CAS  Google Scholar 

  5. Garderet L, Labopin M, Gorin N, Polge E, Baruchel A, Meloni G et al. Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2004; 105: 405–409.

    Article  Google Scholar 

  6. Neudorf S, Sanders J, Kobrinsky N, Alonzo T, Buxton A, Gold S et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 2004; 103: 3655–3661.

    Article  CAS  Google Scholar 

  7. Willemze A, Geskus R, Noordijk E, Kal H, Egeler R, Vossen J . HLA-identical hematopoietic stem cell transplantation for acute leukemia in children: less relapse with higher biologically effective dose of TBI. Bone Marrow Transplant 2007; 40: 319–327.

    Article  CAS  Google Scholar 

  8. Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B et al. Improved outcome after relapse in children with acute myeloid leukemia. Br J Haematol 2007; 36: 229–236.

    Article  Google Scholar 

  9. Eapen M, Rubinstein P, Zhang M, Camitta B, Stevens C, Cairo M et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 2006; 24: 145–151.

    Article  Google Scholar 

  10. Eapen M, Rubinstein P, Zhang M, Stevens C, Kurtzberg J, Scaradavou A et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: a comparison study. Lancet 2007; 369: 1947–1954.

    Article  Google Scholar 

  11. Meshinchi S, Leisenring W, Carpenter P, Woolfrey A, Sievers E, Radich J et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2003; 9: 706–713.

    Article  Google Scholar 

  12. Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16: 78–85.

    Article  CAS  Google Scholar 

  13. de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005; 23: 120–126.

    Article  CAS  Google Scholar 

  14. Gamis A, Woods W, Alonzo T, Buxton A, Lange B, Barnard D et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol 2003; 21: 3415–3422.

    Article  Google Scholar 

  15. Rao A, Hills R, Stiller C, Gibson B, de Graaf S, Hann I et al. Treatment for myeloid leukemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006; 132: 576–583.

    Article  CAS  Google Scholar 

  16. Smith F, King R, Nelson G, Wagner J, Robertson K, Sanders J et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 2002; 16: 716–724.

    Article  Google Scholar 

  17. Locatelli F, Nollke P, Zecca M, Korthof E, Lanino E, Peters C et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005; 105: 410–419.

    Article  CAS  Google Scholar 

  18. Yoshimi A, Bader P, Matthes-Martin S, Stary J, Sedlacek P, Duffner U et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005; 19: 971–977.

    Article  CAS  Google Scholar 

  19. Hasle H, Alonzo T, Auvrignon A, Behar C, Chang M, Creutzig U et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood 2007; 109: 4641–4647.

    Article  CAS  Google Scholar 

  20. Woodard P, Barfield R, Hale G, Horwitz E, Leung W, Ribeiro R et al. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer 2006; 47: 931–935.

    Article  Google Scholar 

  21. Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer H et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336–342.

    Article  CAS  Google Scholar 

  22. Sauer M, Zeidler C, Meissner B, Rehe K, Hanke A, Welte K et al. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan, and melphalan in a preparative regimen for children and adolescents with Shwachmann Diamond syndrome. Bone Marrow Transplant 2007; 39: 143–147.

    Article  CAS  Google Scholar 

  23. Choi S, Boxer L, Pulsipher M, Roulston D, Hutchinson R, Yanik G et al. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplant 2005; 35: 473–477.

    Article  CAS  Google Scholar 

  24. Wagner J, Eapen M, MacMillan M, Harris R, Pasquini R, Boulad F et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2006; 109: 2256–2262.

    Article  Google Scholar 

  25. Pulsipher M . Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer 2004; 43: 523–533.

    Article  Google Scholar 

  26. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al. Outcomes of reduced intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969–2976.

    Article  CAS  Google Scholar 

  27. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686–4692.

    Article  CAS  Google Scholar 

  28. Cortes J, Jabbour E, Kantarjian H, Yin C, Shan J, O'brien S et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007; 110: 4005–4011.

    Article  CAS  Google Scholar 

  29. Oehler V, Gooley T, Snyder D, Johnston L, Lin A, Cummings C et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109: 1782–1789.

    Article  CAS  Google Scholar 

  30. Laane E, Derolf A, Bjorklund E, Mazur J, Everaus H, Soderhall S et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 2006; 91: 833–836.

    PubMed  Google Scholar 

  31. Scholl S, Loncarevic I, Krause C, Clement J, Hoffken K, Sayer H . Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation. J Cancer Res Clin Oncol 2005; 131: 279–283.

    Article  Google Scholar 

  32. Lengfelder E, Saussele S, Weisser A, Buchner T, Hehlmann R . Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol 2005; 56: 261–274.

    Article  Google Scholar 

  33. Goulden N, Virgo P, Grimwade D . Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now. Br J Haematol 2006; 134: 273–282.

    Article  Google Scholar 

  34. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814–819.

    Article  CAS  Google Scholar 

  35. Majhail N, Brunstein C, Wagner J . Double umbilical cord blood transplantation. Curr Opin Immunol 2006; 18: 571–575.

    Article  CAS  Google Scholar 

  36. Ness K, Bhatia S, Baker K, Francisco L, Carter A, Forman S et al. Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study. Arch Pediatr Adolesc Med 2005; 159: 706–713.

    Article  Google Scholar 

  37. Felder-Puig R, Peters C, Matthes-Martin S, Lamche M, Felsberger C, Gadner H et al. Psychosocial adjustment of pediatric patients after allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 24: 75–80.

    Article  CAS  Google Scholar 

  38. Cohen A, van Lint M, Uderzo C, Rovelli A, Lavagetto A, Vitale V et al. Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood. Bone Marrow Transplant 1995; 15: 343–348.

    CAS  PubMed  Google Scholar 

  39. Lowe T, Bhatia S, Somlo G . Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1121–1134.

    Article  Google Scholar 

  40. Carter A, Robison L, Francisco L, Smith D, Grant M, Baker K et al. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant 2006; 37: 1023–1029.

    Article  CAS  Google Scholar 

  41. Gurney J, Ness K, Rosenthal J, Forman S, Bhatia S, Baker K . Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the Bone Marrow Transplant Survivor study. Cancer 2006; 106: 1402–1408.

    Article  Google Scholar 

  42. Baker K, Ness K, Steinberger J, Carter A, Francisco L, Burns L et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 2007; 109: 1765–1772.

    Article  CAS  Google Scholar 

  43. Bhatia S, Louie A, Bhatia R, O'Donnell M, Fung H, Kashyap A et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464–471.

    Article  CAS  Google Scholar 

  44. Bhatia S, Francisco L, Carter A, Sun C, Baker K, Gurney J et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784–3792.

    Article  CAS  Google Scholar 

  45. Grigg A, Gibson J, Bardy P, Reynolds J, Shuttleworth P, Koelmeyer R et al. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant 2007; 13: 560–567.

    Article  CAS  Google Scholar 

  46. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387–9393.

    Article  CAS  Google Scholar 

  47. Flynn C, Hirsch B, Defor T, Barker J, Miller J, Wagner J et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007; 82: 867–872.

    Article  Google Scholar 

  48. Blaise D, Vey N, Faucher C, Mohty M . Current status of reduced-intensity-conditioning and allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2007; 92: 533–541.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Shenoy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shenoy, S., Smith, F. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplant 41, 141–148 (2008). https://doi.org/10.1038/sj.bmt.1705961

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705961

Keywords

This article is cited by

Search

Quick links